Aug 2026· ACS Nano· Vol 20 33, pp.
23296-23313
· 1 citation· 44 references
Medicine
TL;DR
A dual-targeting LNP engineering strategy that integrates high-throughput compositional screening with surface conjugation of β cell-specific targeting ligands to enable selective gene delivery to pancreatic β cells is developed and establishes a versatile platform for RNA therapeutics and gene-editing applications in a pro-inflammatory type 1 diabetes context.
Abstract
Beyond their deployment as COVID-19 vaccines, lipid nanoparticles (LNPs) have emerged as versatile vehicles for therapeutic nucleic acid delivery. However, achieving efficient and cell-targeted transfection in extrahepatic tissues, particularly pancreatic β cells, remains a major challenge. Here, we develop a dual-targeting LNP engineering strategy that integrates high-throughput compositional screening with surface conjugation of β cell-specific targeting ligands to enable selective gene delivery to pancreatic β cells. Compositional optimization identified LNP formulations that achieved over a 148-fold increase in β cell transfection efficiency in vitro and more than an 8-fold increase in pancreatic selectivity in vivo compared to the Moderna LNP formulation. Surface conjugation of the ZnT8-specific monoclonal antibody (mAb43), which recognizes the zinc transporter ZnT8 highly expressed on murine β cells, further increased pancreatic transgene expression by more than 2-fold and achieved over 70% β cell transfection in murine models. To improve translational potential, we conjugated a high-affinity camelid single-domain antibody (4hD29 nanobody) targeting dipeptidyl peptidase-6 (DPP6), a biomarker enriched on human β cells, to compositionally optimized LNPs to deliver human STAT2-siRNA. These dual-targeting LNPs reduced STAT2 expression in human β cells under IFN-α stimulation to below baseline levels observed in unstimulated controls and induced > 4-fold increase in PDL1 expression. Together, this integrated LNP design for β cell-directed gene delivery establishes a versatile platform for RNA therapeutics and gene-editing applications in a pro-inflammatory type 1 diabetes context.
The importance of formulation optimization in improving nucleic acid delivery is highlighted and practical insights for enhancing peptide- and lipid-based therapeutic platforms are provided.
D. Daniele, Z. Hein, O. Saher et al.· International Journal of Pha...· 0 citations
The integration of rational material design, high-throughput screening, artificial intelligence, and interdisciplinary collaboration will be essential to advance next-generation targeted in vivo mRNA cell therapies toward clinical translation.
Danyang Wang, Yumin Li, Jinfeng Deng et al.· Drug Delivery· 0 citations
This study develops a class of ionizable cholesterol derivatives by conjugating biocompatible dimethylated amino acids to cholesterol through a cleavable linker, thereby integrating the structural role of cholesterol and the pH‐responsive ionization of ions into a single molecule.
This study successfully develops an optimized formulation with reduced hepatic off-target effects, which holds great promise for the intramuscular delivery of circRNA-based vaccines and therapeutics.
Jie Yang, Yi-Jia Hao, Si-Ying Long et al.· Lab on a Chip· 0 citations
This study proposes an application-oriented re-engineering strategy that leverages the clinically validated SM-102 platform, enabling rational LNP optimization for diverse mRNA delivery and therapeutic scenarios and recommends SM-102/DSPC and SM-102/DOPE LNPs as preferred formulations for RAW 264.7 macrophages and IGRO...
Xin-Xin Yan, Li-Xin Lin, Yi-Fan Zhang et al.· Journal of Controlled Releas...· 0 citations
A modular DBCO-azide click-chemistry approach is developed to functionalize LNPs with a high-affinity CD4 nanobody, enabling precise CD4 receptor-directed delivery to human CD4+ T cells, establishing CD4-nanobody LNPs as a versatile platform for targeted mRNA and gene-editing delivery.
Maaike De Cock, Elianne Burg, Sarah Gerlo et al.· Advanced Healthcare Material...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.